SMALP BZ25

Order number: 18611

€246.00*

Prices plus VAT plus shipping costs

Ready to ship today

Weight

Quantity

Description

The SMALP BZ series was developed in collaboration with Prof. Bert Klumperman from Nanosene, a spinout company of Stellenbosch University in South Africa. The goal was to create SMALPs that are synthesized via RAFT polymerization, achieving a better defined polymer size and a low dispersity (narrow chain length distribution). This is a significant improvement over previous SMALPs. The SMALP BZs are thus more efficient in dissolving the cell membranes and increasing protein yield.
After successful solubilization of the membrane protein, the protein can be purified using affinity chromatography. For membrane protein purification we recommend using the Rho1D4-tag. Cube Biotech offers matching products for this purpose.

Datasheets

Features
Usage	Membrane protein solubilization & stabilization
Full-Name	Poly(styrene-co-maleic acid-co-25%(N-benzyl)maleimide) copolymer, sodium salt in 50 mM HEPES, pH 7.5
Formula Weight	5,500 g/mol
Buffer	50 mM HEPES
pH	7.5
State	Lyophilized Powder
Recommended concentration range upon use	1% to 5%
Solubility	> 10 % in H₂O
Color	White to slightly yellow
Odor	Odorless
Shipping Temperature	ambient temperature“
Long-term Storage (lyophilized copolymer)	-20°C for several years
Short-term Storage (dissolved copolymer)	2-8°C for several days

Lab Results

BZ SMA Westernblot — **Figure 1:** Shown is the blot activity of a Rho1d4-Tag purified full-length human GPCR expressed in HEK cells. The GPCR was solubilized using SMALP BZ25 – 40 as well as SMALP 200 and Sulfo-SMA as control. The isolation blot reveals SMALP BZ40 as copolymer for most efficient purification.

SMALP Screening assay 2 — **Figure 2:** Shown is the blot activity of a Rho1d4-Tag purified unmodified human membrane protein expressed in HEK cells containing one transmembrane helix. The membrane protein was solubilized using SMALP BZ25 to 40 as well SMALP 200 as control. Even though the solubilization blot points to SMALP BZ40 and SMALP 200 as copolymer of choice, the isolation blot reveals SMALP BZ25 as copolymer for most efficient purification.

SMALP BZ25 Chemical Structure — **Figure 3:** General structure of the SMALP BZ-Polymers.

Comparison of Hydrophobicity between copolymers of the SMALP BZ series — **Figure 4:** Chart of the increasing hydrodrophobicity of the SMALP BZ polymer series. The increase of the ratio of N-benzylmaleimide in the polymer chain increases the hydrophobicity of the polymers and thus leads to different interaction patterns with the cell membrane. And as different membrane proteins prefer different membrane environments, each level of hydrophobicity is optimal for the solubilization of different membrane proteins. This changing of the ratio of N-benzylmaleimide is what differentiates the SMALPs BZ25 (25%), BZ30 (30%), BZ35 (35%) and BZ40 (40%).

Video

Watch our video on the use of synthetic polymers for membrane protein solubilization. It demonstrates the use with SMALP.

FAQ

Can I have the datasheet for SMALP BZ25

Yes of course, you can download it here.

Is SMALP BZ25 from Cube Biotech ready to use?

Yes, our SMALP BZ25 is ready to use. You can start directly with the solubilization. Read our protocol for more information.

Which pH is suitable for SMALP BZ25?

For SMALP BZ25 a pH of 7.5 is recommended.

Which concentrations of SMALP BZ25 should I use for my protein?

In general, we advise you to add 2,5 % SMALP BZ25 to your solution. But the optimal conditions have to be screened by yourself. In general you should not go below 1% or over 5%. Please refer to our Membrane Protein Solubilization Protocol for more information. Or simply ask our support team.

Disclaimer

Patent Pending
The purchaser is licensed under those patents to use the SMALP BZ25; for the manufacture of lipid particles and to use SMALP BZ25 so manufactured for the purpose of research and development of proteins, including their production (including purification and solubilization), screening, testing, analysis, characterization (including structural analysis and characterization), including for the purpose of drug screening, but not for the purpose of delivery of agents to humans or other animals for therapeutic, diagnostic, prophylactic purposes, which uses are specifically prohibited.